Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
SNTA [NASD]
Synta Pharmaceuticals Corp.
Index- P/E- EPS (ttm)-1.02 Insider Own4.00% Shs Outstand108.90M Perf Week1.06%
Market Cap311.45M Forward P/E- EPS next Y-0.93 Insider Trans32.32% Shs Float68.65M Perf Month-10.63%
Income-90.00M PEG- EPS next Q-0.21 Inst Own24.00% Short Float16.98% Perf Quarter-19.44%
Sales- P/S- EPS this Y-19.80% Inst Trans13.32% Short Ratio9.76 Perf Half Y-33.80%
Book/sh0.79 P/B3.62 EPS next Y-4.50% ROA-86.40% Target Price10.88 Perf Year-34.10%
Cash/sh1.10 P/C2.61 EPS next 5Y0.00% ROE-147.10% 52W Range2.54 - 7.22 Perf YTD-45.42%
Dividend- P/FCF- EPS past 5Y14.30% ROI- 52W High-61.01% Beta2.41
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin- 52W Low10.83% ATR0.18
Employees134 Current Ratio3.70 Sales Q/Q- Oper. Margin- RSI (14)45.28 Volatility7.67% 6.13%
OptionableYes Debt/Eq0.19 EPS Q/Q42.40% Profit Margin- Rel Volume0.56 Prev Close2.86
ShortableYes LT Debt/Eq0.08 EarningsNov 06 BMO Payout- Avg Volume1.19M Price2.82
Recom2.70 SMA20-4.45% SMA50-5.84% SMA200-26.32% Volume564,365 Change-1.57%
Mar-13-14Reiterated MLV & Co Buy $10 → $6
Mar-12-14Downgrade Stifel Hold → Sell
Nov-05-13Reiterated MLV & Co Buy $16 → $10
Jun-06-13Reiterated MLV & Co Buy $18.50 → $16
Apr-01-13Reiterated MLV & Co Buy $16 → $18.50
Aug-30-12Initiated Stifel Nicolaus Hold
Jan-05-12Initiated Rodman & Renshaw Mkt Outperform $8
Mar-14-11Reiterated Barclays Capital Equal Weight $2 → $4
Feb-28-11Upgrade Canaccord Genuity Hold → Buy $4.50 → $8
Nov-09-10Initiated MLV Capital Buy $8.50
Aug-26-10Initiated Morgan Joseph Buy $6
May-10-10Upgrade Roth Capital Hold → Buy $4
Feb-19-10Initiated RBC Capital Mkts Sector Perform $5
Feb-17-10Downgrade Roth Capital Buy → Hold $4
Nov-05-09Upgrade Roth Capital Hold → Buy $2 → $4
Feb-27-09Downgrade Wachovia Mkt Perform → Underperform
Feb-27-09Downgrade Roth Capital Buy → Hold $11 → $2
Feb-27-09Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Feb-27-09Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-27-09Downgrade Lazard Capital Buy → Hold
Dec-12-14 08:00AM  Synta Announces Presentation of Results from an Investigator-Sponsored Phase 1 Trial of Ganetespib in HER2+ Metastatic Breast Cancer at the 2014 San Antonio Breast Cancer Symposium Business Wire
Dec-10-14 04:30PM  Synta Reports Inducement Grants to New Chief Operating Officer and New Chief Financial Officer Business Wire
Dec-04-14 05:06PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex EDGAR Online
04:30PM  Synta Strengthens Management Team with Two Executive Appointments Business Wire
Nov-19-14 07:00AM  Synta Announces Presentation on Hsp90 inhibitor Drug Conjugate Platform at 26th EORTC-NCI-AACR Symposium Business Wire
Nov-15-14 01:04PM  SYNTA PHARMACEUTICALS CORP Financials EDGAR Online Financials
Nov-12-14 04:01PM  Synta to Present at the Stifel 2014 Healthcare Conference Business Wire
Nov-09-14 07:09PM  10-Q for Synta Pharmaceuticals Corp. Company Spotlight
Nov-06-14 10:00AM  Synta Pharmaceuticals Corp Earnings Call scheduled for 10:00 am ET today CCBN
08:52AM  Synta beats 3Q profit forecasts AP
07:07AM  Q3 2014 Synta Pharmaceuticals Corp Earnings Release - Before Market Open CCBN
07:00AM  Synta Reports Third Quarter Financial Results and Provides Corporate Update Business Wire
06:08AM  SYNTA PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
Nov-05-14 04:00PM  Will Synta Pharmaceuticals (SNTA) Post a Wider Q3 Loss? Zacks
08:00AM  Synta Announces FDAs Oncologic Drugs Advisory Committee to Discuss Pediatric Uses for Ganetespib Business Wire
Oct-29-14 07:00AM  Synta Announces Initiation of I-SPY 2 TRIAL of Ganetespib in Breast Cancer Business Wire
Oct-27-14 04:01PM  Synta to Host Conference Call and Webcast of Third Quarter 2014 Financial Results on November 6, 2014 Business Wire
Sep-04-14 04:30PM  Synta Reports Inducement Grant to New Chief Executive Officer Business Wire
Aug-06-14 04:23PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex EDGAR Online
10:00AM  Synta Pharmaceuticals Corp Earnings Call scheduled for 10:00 am ET today CCBN
07:07AM  Q2 2014 Synta Pharmaceuticals Corp Earnings Release - Before Market Open CCBN
07:01AM  Synta Names Anne Whitaker Chief Executive Officer Business Wire
07:00AM  Synta Reports Second Quarter Financial Results and Provides Corporate Update Business Wire
06:05AM  SYNTA PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
Jul-30-14 08:00AM  Synta to Host Conference Call and Webcast of Second Quarter 2014 Financial Results on August 6, 2014 Business Wire
Jul-22-14 09:07AM  Synta Pharmaceuticals data positive, says JMP Securities at theflyonthewall.com
Jul-21-14 05:07PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
04:30PM  Synta Announces Advancement of Ganetespib into Phase 3 Extension of AML LI-1 Study for Patients with AML and High-Risk MDS Business Wire
Jul-18-14 04:16PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material EDGAR Online
Jul-08-14 06:54AM  Synta Pharmaceuticals (SNTA) Shares March Higher, Can It Continue? Zacks
Jul-07-14 06:40AM  Synta Pharmaceuticals (SNTA) Jumps: Stock Rises 7.9% Zacks +5.33%
Jun-27-14 04:23PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Jun-24-14 02:31PM  Synta Pharmaceuticals mentioned positively by The Street contributor at theflyonthewall.com -5.16%
02:22PM  A Beaten-Down Biotech Stock Gearing Up for a Big Squeeze Higher at TheStreet
Jun-19-14 04:01PM  Synta to Present at the 9th Annual JMP Securities Healthcare Conference Business Wire
Jun-18-14 03:26PM  5-Star Biotech Stock Watch: Synta Pharmaceuticals Benzinga
Jun-17-14 04:14PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
Jun-16-14 02:27PM  3 Biotech Stocks Backed By Big Money Benzinga
10:00AM  Why A Short Covering Rally Might Come for Synta (SNTA) Stock Zacks
08:47AM  Five Biotech Stocks With Big Potential And Billionaire Believers at Forbes
May-29-14 08:00AM  Synta to Present at the Jefferies 2014 Global Healthcare Conference Business Wire
May-28-14 08:00AM  Synta Announces Presentations at the 2014 American Society for Clinical Oncology (ASCO) Annual Meeting Business Wire
May-23-14 07:58AM  Short Interest is Piling Up in Synta (SNTA) Stock, Time to Panic? Zacks
May-08-14 01:57PM  5 Stocks Under $10 Set to Soar at TheStreet
01:48PM  Synta's Loss Widens 14% As It Reports Its Final Analysis From the GALAXY-1 Trial at Motley Fool
11:22AM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
10:00AM  Synta Pharmaceuticals Corp. Earnings Call scheduled for 10:00 am ET today CCBN
07:18AM  Synta announces final analysis of GALAXY-1 ganetespib trial results theflyonthewall.com
07:18AM  Synta announces final analysis of GALAXY-1 ganetespib trial results at theflyonthewall.com
07:15AM  Synta sees cash resources 'sufficient' to fund operations into 1H15 theflyonthewall.com
07:15AM  Synta sees cash resources 'sufficient' to fund operations into 1H15 at theflyonthewall.com
07:14AM  Synta Pharmaceuticals reports Q1 EPS 28c, consensus 29c at theflyonthewall.com
07:07AM  Q1 2014 Synta Pharmaceuticals Corp. Earnings Release - Before Market Open CCBN
07:01AM  Synta Reports First Quarter 2014 Financial Results and Provides Corporate Update Business Wire
07:00AM  Synta Announces Results From Final Analysis of the GALAXY-1 Trial of Ganetespib in NSCLC Business Wire
06:11AM  SYNTA PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
Apr-29-14 05:00PM  Synta to Host Conference Call and Webcast of First Quarter 2014 Financial Results on May 8, 2013 Business Wire
Apr-28-14 03:26PM  Novel Oncology Treatments Turn Stage 4 Cancer into Chronic Disease State: Citigroup Investment Global Head of Healthcare Research & Analysis Andrew Baum, M.D. Interviews with the Wall Street Transcript Wall Street Transcript
Apr-21-14 10:12AM  Speculative But Attractive Biotechs Insiders Are Buying at Seeking Alpha
Apr-15-14 10:43AM  Stocks: Insiders Buy at Opko Health and Conn's at Minyanville
Apr-14-14 08:37AM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St EDGAR Online
08:00AM  Synta Pharmaceuticals Enters Into Agreement to Sell $5.0 Million in Common Stock Directly to an Affiliate of Synta Board Member Bruce Kovner Business Wire
Apr-07-14 07:30AM  Synta Announces Presentations at the 2014 Annual Meeting of the American Association of Cancer Research Business Wire
Mar-21-14 09:27AM  Synta Pharmaceuticals weakness overdone, says Roth Capital at theflyonthewall.com
05:44AM  Synta Pharmaceuticals Corp. (SNTA) Catches Eye: Stock Jumps 9.5% Zacks
Mar-20-14 08:02PM  Why Synta Pharmaceuticals, Herman Miller, and Tower Semiconductor Jumped Today at Motley Fool +9.47%
04:31PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Sta EDGAR Online
02:34PM  Why Synta Pharmaceuticals Corp. Shares Soared at Motley Fool
05:45AM  Synta Announces Positive Interim Results from the ENCHANT-1 Trial of Ganetespib in Metastatic Breast Cancer at the 9th European Breast Cancer Conference Business Wire
Mar-19-14 08:50PM  Pharma Firms in Focus and Other #Stocks2Watch at Fox Business
Mar-12-14 11:47AM  Why Synta Pharmaceuticals Corp. Plunged Today at Motley Fool -13.83%
06:52AM  Synta Pharma downgraded by Stifel Briefing.com
Mar-11-14 02:55PM  Why Synta Pharmaceuticals Corp. Shares Jumped at Motley Fool
02:01PM  Synta Pharmaceuticals' Management Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
10:00AM  Synta Pharmaceuticals Corp. Earnings Call scheduled for 10:00 am ET today CCBN
09:55AM  Synta Pharmaceuticals Corp. Discusses Q3 2013 Results (Webcast) at Seeking Alpha
07:07AM  Q4 2013 Synta Pharmaceuticals Corp. Earnings Release - Before Market Open CCBN
07:04AM  Synta Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update Business Wire
07:02AM  Synta and QuantumLeap Healthcare Collaborative Announce Selection of Ganetespib for I-SPY 2 TRIAL in Breast Cancer Business Wire
06:06AM  SYNTA PHARMACEUTICALS CORP Files SEC form 10-K, Annual Report EDGAR Online
Mar-06-14 06:46AM  Weakness Seen in Synta Pharmaceuticals (SNTA): Stock Tumbles 13.5% Zacks
Mar-04-14 05:01PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events EDGAR Online
09:33AM  Synta Pharma CEO Sudden Resignation Might Trigger Overhaul at TheStreet
09:12AM  On The Fly: Pre-market Movers at theflyonthewall.com
Mar-03-14 05:51PM  Synta CEO Bahcall Resigns as Board Panel to Run Drugmaker at Bloomberg
04:01PM  Synta Announces Executive Management Changes, Appoints Dr. Paul A. Friedman Director Business Wire
Feb-28-14 01:35PM  Synta to Present on Hsp90-inhibitor Drug Conjugate Platform at the 12th International Congress on Targeted Anticancer Therapies Business Wire -6.36%
Feb-27-14 04:05PM  Synta to Present at Upcoming Conferences Business Wire
Feb-26-14 04:05PM  Synta to Host Conference Call and Webcast of Fourth Quarter and Year-End 2013 Financial Results on March 11, 2014 Business Wire
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development. Its lead drug candidate includes ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; and in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer. The company's product pipeline also comprises Hsp90-inhibitor Drug Conjugate, a novel, proprietary small molecule cancer drug development program; and Elesclomol, a mitochondria-targeting agent that is in Phase 2 clinical trial for ovarian cancer. Its product pipeline in preclinical development stage for inflammatory diseases includes CRACM ion channel inhibitors for rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, allergy, transplant rejection, and other autoimmune diseases and inflammatory conditions; and IL-12/23 inhibitors for inflammatory and autoimmune diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kovner BruceDirectorSep 30Buy3.08300,000923,1308,421,467Oct 01 01:56 PM
Kovner BruceDirectorApr 11Buy4.011,250,0005,012,5008,121,467Apr 14 07:34 PM